Scaling India's Biotech Sector: Opportunities and Regulatory Bottlenecks
India's biotech industry has grown from 500 startups in 2018 to over 10,000 in 2025, supported by the BioE3 Policy. India aims for a $300-billion bioeconomy by 2030. While India is a global leader in generics and vaccines, the sector faces challenges like regulatory complexities, high capital requirements for Phase II clinical trials, and a 'brain drain' of talent. The article suggests a dedicated biotechnology fund, blended-finance structures, and streamlined regulations to help startups scale and compete globally in high-impact areas like precision medicine.
Key Points
- The BioE3 Policy aims to transform India into a $300-billion bioeconomy powerhouse by 2030.
- India provides over 60% of global doses for essential immunizations like DPT and BCG.
- Scaling challenges include fragmented infrastructure and the high cost of clinical validation for startups.
Exam Facts
- Target: $300-billion bioeconomy by 2030.
- Startup Growth: From 500 in 2018 to over 10,000 in 2025.
- FDI: India permits 100% FDI in many biotech segments.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.